Kite Pharma Opens New Facility In El Segundo

Santa Monica-based biopharmaceuticals developer Kite Pharma has opened up a new, 43,500 square foot manufacturing facility in El Segundo, the company said today, to manufacture its cancer immunotherapy products. According to Kite Pharma, the new facility will support production of its chimeric antigen receptor (CAR) and T-cell receptor (TCR) product candidates for clinical trials, along with commercial launch of its lead T-cell product candidate, KTE-C19. The company said the facility is estimated to have the capacity to produce up to 5,000 patient therapies per year, if approved by the FDA.